Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Seres Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.957 Good day and thank you for standing by. At this time, I would like to welcome everyone 00:00:04.957 -- 00:00:10.023 to Sirius Therapeutics' second quarter 2024 earnings conference 00:00:10.023 -- 00:00:15.230 call. All lines have been placed on mute to prevent any background noise. 00:00:15.230 -- 00:00:19.455 After the speaker's remarks, there will be a question and answer session. 00:00:19.455 -- 00:00:24.141 If you would like to ask a question during that time, simply press star followed by the 00:00:24.141 -- 00:00:29.361 number one on your telephone keypad. If you would like to withdraw your question, again, 00:00:29.361 -- 00:00:34.606 press the star 1. Thank you. I would now like to turn the conference over 00:00:34.606 -- 00:00:40.751 to Dr. Carlo Tanzi, Investor Relations. Please go ahead. 00:00:40.751 -- 00:00:45.256 Thank you and good morning. Our press release with the company's second quarter 2024 00:00:45.256 -- 00:00:49.520 financial results and a business update became available at 7 a.m. 00:00:49.520 -- 00:00:53.804 Eastern Time this morning and can be found on the Investors & You section of the company's 00:00:53.804 -- 00:00:59.851 website. The company has also posted an updated corporate presentation to the website. 00:00:59.851 -- 00:01:04.037 I'd like to remind you that we'll be making forward-looking statements, including related 00:01:04.037 -- 00:01:09.065 to the financial terms, timing, and completion of the sale of VALS assets to Nestle 00:01:09.065 -- 00:01:14.853 Health Science, the receipt of future payments and the use of proceeds of the transaction, 00:01:14.853 -- 00:01:19.921 the timing and results of clinical studies and data readouts, development plans and commercial 00:01:19.921 -- 00:01:21.323 ...